FMP
NASDAQ
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
2.21 USD
0.0247 (1.12%)
Valuation Date:
Apr 25, 2024 11:25 AM
Share Price on Valuation Date
$2.21
Stock Beta
1.754
Shares Outstanding
15981700